secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001193125-25-223434
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma cuts workforce ~33%; extends cash runway to mid-2027
--------------------------------------------------------------------

- Workforce reduction of approximately one-third to prioritize three preclinical ADC programs.
- Expected cash runway extended into at least mid-2027 due to restructuring and milestone payments.
- Initial clinical data from STRO-004 (Tissue Factor-targeting exatecan ADC) expected in 2026.
- Restructuring costs estimated at $4.1-4.3 million, with majority paid in Q4 2025.
- Company plans to initiate clinical studies for at least one additional ADC program beyond STRO-004.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000119312525223434/0001193125-25-223434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000119312525223434/stro-20250929.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-223434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer